{"classes":[{"categories":[{"measurements":[{"comment":"NA = Not estimable due to insufficient number of events","groupId":"OG000","lowerLimit":"8.0","upperLimit":"NA","value":"NA"},{"comment":"NA = Not estimable due to insufficient number of events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years and 7 months","title":"Duration of Response (DOR) as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Months"}